EUVIMEDEUVIMED entdecken
Crossref

Urine Tricarboxylic Acid Cycle Metabolites and Risk of End-stage Kidney Disease in Patients With Type 2 Diabetes

Jian-Jun Liu, Sylvia Liu, Huili Zheng, Janus Lee, Resham L Gurung, Clara Chan, Lye Siang Lee, Keven Ang, Jianhong Ching, Jean-Paul Kovalik, Subramaniam Tavintharan, Chee Fang Sum und 3 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Jian-Jun Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Unit, Khoo Teck Puat Hospital, Singapore 768828, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Citric Acid Cycle, Kidney Failure, Chronic, Diabetic Nephropathies. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: KTPH STAR, Singapore National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Metabolites in the tricarboxylic acid (TCA) pathway have pleiotropic functions.

Objective

To study the association between urine TCA cycle metabolites and the risk for chronic kidney disease progression in individuals with type 2 diabetes. Design, setting and participants A prospective study in a discovery (n = 1826) and a validation (n = 1235) cohort of people with type 2 diabetes in a regional hospital and a primary care facility Exposure and Outcome Urine lactate, pyruvate, citrate, alpha-ketoglutarate, succinate, fumarate, and malate were measured by mass spectrometry. Chronic kidney disease progression was defined as a composite of sustained estimated glomerular filtration rate below 15 mL/min/1.73 m2, dialysis, renal death, or doubling of serum creatinine.

Results

During a median of 9.2 (interquartile range 8.1-9.7) and 4.0 (3.2-5.1) years of follow-up, 213 and 107 renal events were identified. Cox regression suggested that urine lactate, fumarate, and malate were associated with an increased risk (adjusted hazard ratio, [95% CI] 1.63 [1.16-2.28], 1.82 [1.17-2.82], and 1.49 [1.05-2.11], per SD), whereas citrate was associated with a low risk (aHR 0.83 [0.72-0.96] per SD) for the renal outcome after adjustment for cardiorenal risk factors. These findings were reproducible in the validation cohort. Noteworthy, fumarate and citrate were independently associated with the renal outcome after additional adjustment for other metabolites.

Conclusion

Urine fumarate and citrate predict the risk for progression to end-stage kidney disease independent of clinical risk factors and other urine metabolites. These 2 metabolites in TCA cycle pathway may play important roles in the pathophysiological network, underpinning progressive loss of kidney function in patients with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Citric Acid CycleKidney Failure, ChronicDiabetic NephropathiesHumansMaleFemaleMiddle AgedAgedDisease ProgressionProspective StudiesRisk FactorsFumaratesBiomarkersMalatesGlomerular Filtration RateLactic Acid

Stichwörter der Autor:innen

citrateend stage kidney diseasefumaratetricarboxylic acid cycletype 2 diabetesurine metabolomics

Substanzen

FumaratesBiomarkersMalatesLactic Acid

Autor:innen und Institutionen

  • Clinical Research Unit, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
  • Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore 169857, Singapore.
  • KK Research Centre, KK Women's and Children's Hospital, Singapore 229899, Singapore.
  • Admiralty Medical Center, Khoo Teck Puat Hospital, Singapore 730676, Singapore.
  • Center for Precision Medicine, The University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Division of Nephrology, Department of Medicine, The University of Texas Health San Antonio, San Antonio, TX 78229, USA.

ORCID-Profile: Su Chi Lim

Förderung

  • KTPH STAR
  • Singapore National Medical Research Council

Zitieren

APA

Liu, J. J., Liu, S., Zheng, H., Lee, J., Gurung, R. L., Chan, C., Lee, L. S., Ang, K., Ching, J., Kovalik, J. P., Tavintharan, S., Sum, C. F., Sharma, K., Coffman, T. M., & Lim, S. C. (2025). Urine Tricarboxylic Acid Cycle Metabolites and Risk of End-stage Kidney Disease in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae199

Vancouver

Liu JJ, Liu S, Zheng H, Lee J, Gurung RL, Chan C, et al. Urine Tricarboxylic Acid Cycle Metabolites and Risk of End-stage Kidney Disease in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae199

BibTeX
@article{Liu2025,
  author = {Liu, Jian-Jun and Liu, Sylvia and Zheng, Huili and Lee, Janus and Gurung, Resham L and Chan, Clara and Lee, Lye Siang and Ang, Keven and Ching, Jianhong and Kovalik, Jean-Paul and Tavintharan, Subramaniam and Sum, Chee Fang and Sharma, Kumar and Coffman, Thomas M and Lim, Su Chi},
  title = {Urine Tricarboxylic Acid Cycle Metabolites and Risk of End-stage Kidney Disease in Patients With Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae199}
}
Kostenlos starten →